The investigators hypothesize that Levetiracetam is as effective as Sulthiame in the treatment of children with BECTS. Patients entering the HEAD-Studie are either treated with Leveitracetam or Sulthiame over a 6 months period. Patients are equally randomised to one of the two treatment regimens. Administration of medication as blinded capsules.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
44
Dr. von Haunersches Kinderspital
München, Germany
To evaluate the efficacy of levetiracetam in the treatment of children with BECTS compared to sulthiame
Time frame: 6 months
Safety and tolerability
Time frame: 6 months
Cognitive effects
Time frame: 6 months
Efficacy on EEG pattern
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.